CG347B

CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research[1][2].

Product Specifications

CAS Number

[1598426-03-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cg347b.html

Concentration

10mM

Purity

98.07

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(NC2(C3=CC=CC=C3)CC2)N=C1)OCC

Molecular Formula

C16H17N3O2

Molecular Weight

283.33

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Christopher M. YATES. Metalloenzyme inhibitor compounds. WO2018165520A1.|[2]Wang W, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020 Sep 2;19 (1) :134. |[3]Cui J, et al. IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021 May 18;12 (6) :501.